Quarterly UpdatesApr 30, 2026, 06:02 AM
ACON Q1 Nociscan Adoption +196% YoY; $2.5M Share Buyback
AI Summary
Aclarion reported strong Q1 2026 operational results, with Nociscan scan volumes increasing 196% year-over-year and 64% sequentially. The company announced a $2.5 million share repurchase program and strengthened its intellectual property with a new AI patent, bringing the total to 64 patents. Aclarion maintains a strong financial position with $19.0 million in cash and no debt, providing a cash runway into H2 2027, and anticipates CLARITY trial interim readout in Q4 2026.
Key Highlights
- Nociscan scan volumes increased 196% year-over-year in Q1 2026.
- Nociscan scan volumes grew 64% sequentially (Q1 2026 vs. Q4 2025).
- Announced a $2.5 million share repurchase program.
- Cash balance of $19.0 million as of March 31, 2026, with no debt.
- Cash runway extended into the second half of 2027.
- Intellectual property portfolio totals 64 issued and pending patents worldwide.
- CLARITY trial interim readout anticipated in Q4 2026.
- Approximately 2,444,871 common shares outstanding as of March 31, 2026.